Risk of cancer in psoriasis: a systematic review and meta‐analysis of epidemiological studies

Pouplard, Claire; Brenaut, E.; Horreau, C.; Barnetche, Thomas; Miséry, Laurent; Richard, M.‐A.; Aractingi, S.; Aubin, F.; Cribier, B.; Joly, P.; Jullien, D.; Maître, Michel; Jp, Ortonne; Paul, C.

doi:10.1111/jdv.12165

Cited by 205 publications

(225 citation statements)

References 46 publications

Supporting

Mentioning

205

Contrasting

Unclassified

Order By: Relevance

“…Notably, patients with psoriasis have an increased risk of squamous cell carcinoma (SIR = 5.3; 95% CI 2.63-10.71) and basal cell carcinoma (SIR = 2.00; 95% CI 1.83-2.20), but not melanoma (SIR = 1.07; 95% CI 0.85-1.35) [26].…”

Section: Cancersmentioning

confidence: 99%

“…Results from a meta-analysis of epidemiologic studies in patients with psoriasis found that the standardized incidence ratio (SIR) of any cancer, excluding nonmelanoma skin cancer (NMSC), was 1.16 (95% confidence interval [CI] 1.07-1.25) [26]. Notably, patients with psoriasis have an increased risk of squamous cell carcinoma (SIR = 5.3; 95% CI 2.63-10.71) and basal cell carcinoma (SIR = 2.00; 95% CI 1.83-2.20), but not melanoma (SIR = 1.07; 95% CI 0.85-1.35) [26].…”

Section: Cancersmentioning

confidence: 99%

See 1 more Smart Citation

Safety of secukinumab in the treatment of psoriasis

Blauvelt

2016

Expert Opinion on Drug Safety

104

View full text Add to dashboard Cite

Introduction: Secukinumab is a human monoclonal antibody that selectively targets and neutralizes interleukin (IL)-17A, a cytokine that is normally involved in mucocutaneous defense against extracellular organisms and is abnormally expressed in psoriasis. In 2015, secukinumab was the first IL-17A inhibitor approved for the treatment of moderate-to-severe psoriasis. Areas covered: This review evaluates the safety profile of secukinumab for the treatment of moderateto-severe psoriasis and its role in the clinical landscape. A literature search was performed for articles published through February 2016; additional data from a pooled safety analysis of 10 Phase II and III secukinumab studies were reviewed. Expert opinion: Collectively, these studies show that secukinumab demonstrates a highly favorable safety profile, especially compared with commonly used psoriasis treatments such as methotrexate and TNF-α blockers. More specifically, secukinumab carries no increased risks for end-organ toxicities, serious infection, multiple sclerosis, reactivation of latent tuberculosis or hepatitis B, leukemia/lymphoma, and nonmelanoma skin cancer. Mucocutaneous candidiasis is a common side effect and occurs at a rate of 3.55/100 subject-years with secukinumab 300 mg, yet these infections usually do not interfere with maintenance of secukinumab therapy. The combination of proven efficacy and safety make secukinumab an excellent new treatment choice for individuals with moderate-to-severe psoriasis.ARTICLE HISTORY

show abstract

Section: Cancersmentioning

confidence: 99%

Section: Cancersmentioning

confidence: 99%

Safety of secukinumab in the treatment of psoriasis

Blauvelt

2016

Expert Opinion on Drug Safety

104

View full text Add to dashboard Cite

show abstract

“…Another meta-analysis found an increased risk of the development of various forms of cancer [69]. PUVA treatment increases the risk of cutaneous squamous cell carcinoma and malignant melanoma.…”

Section: Sheets For the Presentationmentioning

confidence: 99%

Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method

Janknegt¹

2016

J Pharma Care Health Sys

View full text Add to dashboard Cite

The treatment of plaque psoriasis is changing because of the introduction of new treatment options. The goal of this article is to allow a transparent and rational choice of medicines by means of the System of Objectified Judgement Analysis. The following selection criteria (relative weight) were applied: approved indications (40), drug interactions (60), clinical efficacy (400), safety (300), dosage frequency (100) and documentation (100). Acquisition cost was not taken into consideration to allow a preselection on quality aspects only. Adalimumab, etanercept, infliximab and ustekinumab were compared on these criteria. Infliximab and ustekinumab showed the highest scores and are the most suitable medicines for the treatment of severe plaque psoriasis. Of course, cost will play a key role in the final selection in individual hospitals. Weight Approved indications 40 Drug Interactions 60Clinical efficacy 400Safety 300Dosage frequency 100 Documentation 100Total 1000 Selection Criteria Approved IndicationsThe number of licensed indications is a good measure of the applicability and documentation of the drugs. Although this analysis is limited to the treatment of plaque psoriasis, the fact that a drug is approved for (almost) all indications listed below is, from a formulary point of view, advantageous to another drug, which is approved for only one or two applications.The percentage of the maximum score for approved indications was obtained as follows (Table 2): IndicationMaximum Score (%)Plaque psoriasis 50% Psoriatric arthritis 20%Rheumatoid arthritis 10% Spondylitis ankylopoetica 10%Inflammatory bowel disease 10% Drug interactionsInteractions play a role only in patients who use other drugs which may interact with biologicals. However, it is a relevant criterion from a formulary point of view.The score for each drug was dependent on the frequency and severity of observed drug interactions. Clinical efficacyClinical efficacy is always a very important selection criterion for any group of drugs. The score for each drug was derived from the results of double-blind comparative studies. SafetyThe extent and the severity of adverse effects is another important selection criterion for drugs. A distinction was made between "minor" side effects, such as gastrointestinal disturbances or skin reactions, occurring in clinical trials and severe or even life-threatening adverse reactions observed with large scale use of the drugs. The evaluation of the "minor" adverse effects was based on results of double blind comparative clinical studies.

show abstract

“…An increased risk of skin cancer also exists with psoralen and ultraviolet-A (PUVA) or NB-UVB [4]. However, other comorbidities such as tobacco smoking and alcohol use must be considered when measuring the cancer risk in psoriasis [5]. Our patient had received cyclosporine and NB-UVB phototherapy, but no other comorbidities such as tobacco smoking, betel nut chewing, or alcohol use were identified.…”

Section: Introductionmentioning

confidence: 99%

Squamous Cell Carcinoma of the Tongue in a Patient on Ustekinumab as the Treatment of Psoriasis

Chen¹

2017

CRDOA

View full text Add to dashboard Cite

Risk of cancer in psoriasis: a systematic review and meta‐analysis of epidemiological studies

Cited by 205 publications

References 46 publications

Safety of secukinumab in the treatment of psoriasis

Safety of secukinumab in the treatment of psoriasis

Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method

Squamous Cell Carcinoma of the Tongue in a Patient on Ustekinumab as the Treatment of Psoriasis

Contact Info

Product

Resources

About